New and emerging treatments for Alzheimer's disease

Expert Opinion on Emerging Drugs

Volumn 17, Issue 2, 2012, Pages 147-156

  Corbett, Anne ^a   Ballard, Clive ^b  

^a ALZHEIMER'S SOCIETY   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Alzheimer's disease; Clinical trials; Drugs; Treatments

Indexed keywords

ACI 24; AD 01; AD 02; AF 267B; ALZHEIMER DISEASE VACCINE; AZD 103; BAPINEUZUMAB; BRYOSTATIN 1; CAD 106; CEVIMELINE; CRENEZUMAB; DONEPEZIL; EHT 0202; ELND 005; ETAZOLATE; EVP 6124; GALANTAMINE; GSK 933776; HOMOTAURINE; INOSITOL; LADOSTIGIL; MEMANTINE; MUSCARINIC AGENT; NGX 267; NICOTINIC AGENT; PF 04447943; PF 4494700; PIOGLITAZONE; PLACEBO; PONEZUMAB; PSYCHOTROPIC AGENT; RIVASTIGMINE; RO 4909832; ROSIGLITAZONE; SEMAGACESTAT; SOLANEZUMAB; TALSACLIDINE; TARENFLURBIL; UNCLASSIFIED DRUG; UNINDEXED DRUG; V 950; VANUTIDE CRIDIFICAR; XANOMELINE;

ACTIVE IMMUNIZATION; AGGRESSION; AGITATION; ALZHEIMER DISEASE; CLINICAL TRIAL (TOPIC); COGNITION; COGNITIVE REHABILITATION; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXERCISE; GASTROINTESTINAL SYMPTOM; HUMAN; IMMUNOTHERAPY; META ANALYSIS (TOPIC); MILD COGNITIVE IMPAIRMENT; NERVE CELL; NEUROIMAGING; NEUROPSYCHOLOGY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PALLIATIVE THERAPY; PASSIVE IMMUNIZATION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; UNSPECIFIED SIDE EFFECT;

ALZHEIMER DISEASE; ANIMALS; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DEMENTIA; DRUG EVALUATION, PRECLINICAL; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84861607313     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.2012.675327     Document Type: Review

References (76)

1. Available from: www.alz.co.uk/adi/pdf/prevalence.pdf
2. Wimo A, Prince M. World Alzheimer Report 2010. Alzheimer's Disease International; London: 2010
3. Ballard C, Corbett A, Sharp S. Aligning the evidence with practice: NICE guidelines for drug treatment of Alzheimer's disease. Expert Rev Neurother 2011;11:327-9
4. Perry EK, Perry RH, Blessed G, Tomlinson G. Necropsy evidence of central cholinergic deficits in senile dementia. Lancet 1977;1:189 (Pubitemid 8020501)
5. Lawlor BA, Davis KL. Does modulation of glutamatergic function represent a viable therapeutic strategy in Alzheimer's disease? Biol Psychiatry 1992;31:337-50
6. Loy C, Schneider L. Galantamine for Alzheimer's disease and mild cognitive impairment. Cochrane Database Syst Rev 2006(1):CD001747
7. Birks J, Grimley Evans J, Iakovidou V, et al. Cochrane Database Syst Rev 2009(2):CD001191
8. Birks J, Harvey RJ. Donepezil for dementia due to Alzheimer's disease. Cochrane Database of Syst Rev 2006(1):CD001190
9. Doody RS, Tariot PN, Pfeiffer E, et al. Meta-analysis of six-month memantine trials in Alzheimer's disease. Alzheimers Demen 2007;3:7-17 (Pubitemid 46076022)
10. Available from: www.nice.org.uk/TA111
11. Rodda J, Morgan S, Walker Z. Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer's disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine. Int Psychogeriatr 2009;21:813-24
12. Gauthier S, Feldman H, Hecker J, et al. Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer's disease. Donepezil MSAD Study Investigators Group. Int Psychogeriatr 2002;14:389-404 (Pubitemid 36331605)
13. Ballard C, Sorensen S, Sharp S. Pharmacological therapy for people with Alzheimer's disease: the balance of clinical effectiveness, ethical issues and social and healthcare costs. J Alzheimers Dis 2007;12:53-9 (Pubitemid 47396304)
14. Rockwood K, Fay S, Song X, et al. Attainment of treatment goals by people with Alzheimer's disease receiving galantamine: a randomized controlled trial. Video-Imaging Synthesis of Treating Alzheimer's Disease (VISTA) Investigators. CMAJ 2006;174:1099-105
15. Rockwood K, Fay S, Gorman M, et al. The clinical meaningfulness of ADAS-Cog changes in Alzheimer's disease patients treated with donepezil in an open-label trial. BMC Neurol 2007;7:26
16. Ballard CG, Chalmers KA, Todd C, et al. Cholinesterase inhibitors reduce cortical abeta in dementia with lewy bodies. Neurology 2007;68:1726-9 (Pubitemid 46763261)
17. Chalmers KA, Wilcock GK, Vinters HV, et al. Cholinesterase inhibitors may increase phosphorylated tau in Alzheimer's disease. J Neurol 2009;256:717-20
18. Tariot PN, Farlow MR, Grossberg GT, et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 2004;291:317-24 (Pubitemid 38101604)
19. Atri A, Shaughnessy LW, Locascio JJ, Growdon JH. Long-term course and effectiveness of combination therapy in Alzheimer disease. Alzheimer Dis Assoc Disord 2008;22:209-21
20. Wilcock GK, Ballard CG, Cooper JA, Loft H. Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer's disease: a pooled analysis of 3 studies. J Clin Psychol 2008;69:341-8 (Pubitemid 351549385)
21. Hock C, Maddalena A, Raschig A, et al. Treatment with the selective muscarinic m1 agonist talsaclidine decreases cerebrospinal fluid levels of A beta 42 in patients with Alzheimer's disease. Amyloid 2003;10(1):1-6 (Pubitemid 36520922)
22. Bodick NC, Offen WW, Levey AI, et al. Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease. Arch Neurol 1997;54:465-73 (Pubitemid 27172867)
23. Cappai R, Barnham KJ. Delineating the mechanism of Alzheimer's disease A beta peptide neurotoxicity. Neurochem Res 2008;33:526-32 (Pubitemid 351230455)
24. Pimplikar SW. Reassessing the amyloid cascade hypothesis of Alzheimer's disease. Int J Biochem Cell Biol 2009;41:1261-8
25. Dubois B, Feldman HH, Jacova C, et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 2007;6:734-46 (Pubitemid 47058377)
26. Tomita T. Secretase inhibitors and modulators for Alzheimer's disease treatment. Expert Rev Neurother 2009;9:661-79
27. Landreth G, Jiang Q, Mandrekar S, Heneka M. PPARgamma agonists as therapeutics for the treatment of Alzheimer's disease. Neurotherapeutics 2008;5:481-9 (Pubitemid 351952487)
28. M Gold M, Alderton C, Zvartau-Hind ME, et al. Effects of rosiglitazone as monotherapy in APOE4-stratified subjects with mild-to-moderate Alzheimer's disease. Alzheimers Dement 2009;5:86
29. Henley DB, May PC, Dean RA, Siemers ER. Development of semagacestat (LY450139), a functional gamma-secretase inhibitor, for the treatment of Alzheimer's disease. Expert Opin Pharmacother 2009;10:1657-64
30. Green RC, Schneider LS, Amato A, et al. Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. JAMA 2009;302:2557-64
31. Griffiths HH, Morten IJ, Hooper NM. Emerging and potential therapies for Alzheimer's disease. Expert Opin Ther Targets 2008;12:693-704 (Pubitemid 351877298)
32. Marcade M, Bourdin J, Loiseau N, et al. Etazolate, a neuroprotective drug linking GABA(A) receptor pharmacology to amyloid precursor protein processing. J Neurochem 2008;106:392-404 (Pubitemid 351840218)
33. Desire L, Marcade M, Peillon H, et al. Clinical trials of EHT 0202, a neuroprotective and procognitive alpha-secretase stimulator for Alzheimer's disease. Alzheimers Dement 2009;54:255
34. Gilman S, Koller M, Black RS, et al. Clinical effects of abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 2005;64:1553-62 (Pubitemid 40617691)
35. Holmes C, Boche D, Wilkinson D, et al. Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 2008;372:216-23 (Pubitemid 351978111)
36. Schneeberger A, Mandler M, Otawa O, et al. Development of affitope vaccines for Alzheimer's disease (AD)-from concept to clinical testing. J Nutr Health Aging 2009;13:264-7
37. Winblad B, Minthon L, Floesser A, et al. Results of the first-in-man study with the active Abeta immunotherapy CAD106 in Alzheimer patients. Alzheimers Dement 2009;54:113
38. Wilcock DM, Colton CA. Anti-amyloid-beta immunotherapy in Alzheimer's disease: relevance of transgenic mouse studies to clinical trials. J Alzheimers Dis 2008;15:555-69
39. Relkin NR, Szabo P, Adamiak B, et al. 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease. Neurobiol Aging 2009;30:1728-36
40. Siemers ER, Friedrich S, Dean RA, et al. Safety, tolerability and biomarker effects of an abeta monoclonal antibody administered to patients with Alzheimer's disease. Alzheimers Dement 2008;44:774
41. Salloway S, Sperling R, Gilman S, et al. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 2009;73:2061-70
42. Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol 2007;8:101-12 (Pubitemid 46432529)
43. Shankar GM, Li S, Mehta TH, et al. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med 2008;14:837-42
44. Aisen PS, Saumier D, Briand R, et al. A phase II study targeting amyloid-beta with 3APS in mild-to-moderate Alzheimer disease. Neurology 2006;67:1757-63 (Pubitemid 44900749)
45. Aisen P, Gauthier S, Ferris S, et al. A phase III, placebo-controlled, double-blind, randomized trial of tramiprosate in the clinical management of patients with mild-to-moderate Alzheimer's disease (the Alphase study). 61st American Academy of Neurology annual meeting; April 25-May 02 2009; Seattle, WA, USA. S32.003
46. McLaurin J, Kierstead ME, Brown ME, et al. Cyclohexanehexol inhibitors of Abeta aggregation prevent and reverse Alzheimer phenotype in a mouse model. Nat Med 2006;12:801-8 (Pubitemid 44050070)
47. Garzone P, Koller M, Pastrak A, et al. Oral amyloid anti-aggregating agent ELND005 is measurable in CSF and brain of healthy adult men. Alzheimers Dement 2009;5(4):P323
48. Ritchie CW, Bush AI, Mackinnon A, et al. Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch Neurol 2004;61:776
49. Lannfelt L, Blennow K, Zetterberg H, et al. Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial. Lancet Neurol 2008;7:779-86
50. Tariot PN, Schneider LS, Cummings J, et al. Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease. Arch Gen Psychiatry 2011;68:853-61
51. Mudher A, Shepherd D, Newman TA, et al. GSK-3beta inhibition reverses axonal transport defects and behavioural phenotypes in Drosophila. Mol Psychiatry 2004;9:522-30 (Pubitemid 38903508)
52. Leroy K, Ando K, Heraud C, et al. Lithium treatment arrests the development of neurofibrillary tangles in mutant tau transgenic mice with advanced neurofibrillary pathology. J Alzheimers Dis 2010;19:705-19
53. Macdonald A, Briggs K, Poppe M, et al. Feasibility and tolerability study of lithium in Alzheimer's disease. Int J Geriatr Psychiatry 2008;23:704-11
54. Gura T. Hope in Alzheimer's fight emerges from unexpected places. Nat Med 2008;14:894
55. Jones RW. Dimebon disappointment. Alzheimers Res Ther 2010;2:25
56. Weinreb O, Amit T, Bar-Am O, Youdim MB. A novel anti-Alzheimer's disease drug, ladostigil neuroprotective, multimodal brain-selective monoamine oxidase and cholinesterase inhibitor. Int Rev Neurobiol 2011;100:191-215
57. Available from: http://www.news-medical.net/news/20090923/CERE-110-trial- to-stop-the-progression-of-Alzheimers-disease.aspx
58. Kurakhmaeva KB, Djindjikhashvili IA, Petrov VE, et al. Brain targeting of nerve growth factor using poly(butyl cyanoacrylate) nanoparticles. J Drug Target 2009;17:564-74
59. Blurton-Jones M, Kitazawa M, Martinez-Coria H, et al. Neural stem cells improve cognition via BDNF in a transgenic model of Alzheimer disease. Proc Natl Acad Sci USA 2009;106:13594-9
60. Maher-Edwards G, Zvartau-Hind M, Hunter AJ, et al. Double-blind, controlled phase II study of a 5-HT6 receptor antagonist, SB-742457, in Alzheimer's disease. Curr Alzheimer Res 2010;7:374-85
61. Bates KA, Verdile G, Li QX, et al. Clearance mechanisms of Alzheimer's amyloid-beta peptide: implications for therapeutic design and diagnostic tests. Mol Psychiatry 2009;14:469-86
62. Hemming ML, Selkoe DJ, Farris W. Effects of prolonged angiotensin-converting enzyme inhibitor treatment on amyloid beta-protein metabolism in mouse models of Alzheimer disease. Neurobiol Dis 2007;26:273-81 (Pubitemid 46436503)
63. Khachaturian AS, Zandi PP, Lyketsos CG, et al. Antihypertensive medication use and incident Alzheimer disease: the Cache County Study. Arch Neurol 2006;63:686-92
64. Li NC, Lee A, Whitmer RA, et al. Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis. BMJ 2010;340:5465
65. Domercq M, Matute C. Neuroprotection by tetracyclines. Trends Pharmacol Sci 2004;25:609-12 (Pubitemid 39458165)
66. Loeb MB, Molloy DW, Smieja M, et al. A Randomized, controlled trial of doxycycline and rifampin for patients with Alzheimer's disease. J Am Geriatr Soc 2004;52:381-7 (Pubitemid 38339518)
67. McClean PL, Parthsarathy V, Faivre E, Holscher C. The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease. J Neurosci 2011;31:6587-94
68. Li Y, Duffy KB, Ottinger MA, et al. GLP-1 receptor stimulation reduces amyloid-beta peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer's disease. J Alzheimers Dis 2010;19:1205-19
69. Clare L, Linden DE, Woods RT, et al. Goal-oriented cognitive rehabilitation for people with early-stage Alzheimer disease: a single-blind randomized controlled trial of clinical efficacy. Am J Geriatr Psychiatry 2010;18:928-39
70. Yu F, Rose KM, Burgener SC, et al. Cognitive training for early-stage Alzheimer's disease and dementia. J Gerontol Nurs 2009;35:23-9
71. Spector A, Thorgrimsen L, Woods B, et al. Efficacy of an evidence-based cognitive stimulation therapy programme for people with dementia: randomised controlled trial. Br J Psychiatry 2003;183:248-54 (Pubitemid 37070181)
72. Owen AM, Hampshire A, Grahn JA, et al. Putting brain training to the test. Nature 2010;465:775-8
73. Erickson KI, Voss MW, Prakash RS, et al. Exercise training increases size of hippocampus and improves memory. Proc Natl Acad Sci USA 2011;108:3017-22
74. Baker LD, Frank LL, Foster-Schubert K, et al. Effects of aerobic exercise on mild cognitive impairment: a controlled trial. Arch Neurol 2010;67:71-9
75. Lautenschlager NT, Cox KL, Flicker L, et al. Effect of physical activity on cognitive function in older adults at risk for Alzheimer disease: a randomized trial. JAMA 2008;300:1027-37
76. Dubois B, Feldman HH, Jacova C, et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 2007;6:734-46 (Pubitemid 47058377)